Trending Stock News

Insider Selling: Moody's (MCO)’s President and CEO Raymond Mcdaniel Unloaded 10,000 shares; 9 Bullish Analysts Covering Teva Pharmaceutical Industries Limited (TEVA)

Moody's Corporation (NYSE:MCO) Logo

Among 35 analysts covering Teva Pharma (NYSE:TEVA), 9 have Buy rating, 8 Sell and 18 Hold. Therefore 26% are positive. Teva Pharma had 153 analyst reports since July 21, 2015 according to SRatingsIntel. The firm has “Underperform” rating by Credit Suisse given on Monday, November 6. The rating was downgraded by Maxim Group to “Hold” on Friday, January 6. Susquehanna maintained it with “Buy” rating and $24.0 target in Thursday, January 25 report. RBC Capital Markets upgraded the stock to “Hold” rating in Friday, February 9 report. The stock of Teva Pharmaceutical Industries Limited (NYSE:TEVA) earned “Hold” rating by Guggenheim on Tuesday, December 12. The firm earned “Perform” rating on Thursday, August 3 by Oppenheimer. Piper Jaffray maintained Teva Pharmaceutical Industries Limited (NYSE:TEVA) rating on Thursday, August 3. Piper Jaffray has “Hold” rating and $2300 target. The stock has “Buy” rating by Mizuho on Thursday, August 25. On Thursday, June 22 the stock rating was maintained by Jefferies with “Hold”. On Monday, September 18 the stock rating was maintained by RBC Capital Markets with “Underperform”. See Teva Pharmaceutical Industries Limited (NYSE:TEVA) latest ratings:

07/05/2018 Broker: Mizuho Rating: Buy New Target: $27.0000 Maintain
07/05/2018 Broker: Morgan Stanley Old Rating: Equal-Weight New Rating: Equal-Weight Old Target: $18 Maintain
03/05/2018 Broker: Wells Fargo Rating: Sell New Target: $16.5000 Maintain
20/04/2018 Broker: Mizuho Rating: Buy New Target: $27.0000 Maintain
25/03/2018 Broker: RBC Capital Markets Rating: Hold New Target: $16.0000 Maintain
20/03/2018 Broker: Jefferies Rating: Hold New Target: $19.0 Maintain
13/03/2018 Broker: Guggenheim Rating: Hold Maintain
15/02/2018 Broker: Mizuho Rating: Buy New Target: $23.0 Maintain
12/02/2018 Broker: BTIG Research Rating: Sell New Target: $17.0 Maintain
12/02/2018 Broker: Credit Suisse Old Rating: Neutral New Rating: Outperform Upgrade

The stock increased 0.79% or $1.35 during the last trading session, reaching $172.24. About 741,990 shares traded or 0.73% up from the average. Moody's Corporation (NYSE:MCO) has risen 43.20% since May 17, 2017 and is uptrending. It has outperformed by 31.65% the S&P500.

More notable recent Moody's Corporation (NYSE:MCO) news were published by: Streetinsider.com which released: “Buffett’s Berkshire 13F Confirms Increase in Apple (AAPL) Stake Along with Increase in Holdings of Teva (TEVA) (More..)” on May 15, 2018, also Fool.com with their article: “3 Stocks for Warren Buffett Fans” published on May 17, 2018, Seekingalpha.com published: “Moody’s Corporation 2018 Q1 – Results – Earnings Call Slides” on April 30, 2018. More interesting news about Moody's Corporation (NYSE:MCO) were released by: Profitconfidential.com and their article: “Is Tesla Stock Overrated or Underrated?” published on May 17, 2018 as well as Seekingalpha.com‘s news article titled: “Moody’s (MCO) CEO Ray McDaniel on Q1 2018 Results – Earnings Call Transcript” with publication date: April 28, 2018.

Since November 22, 2017, it had 0 insider buys, and 12 insider sales for $32.43 million activity. 3,500 shares valued at $588,000 were sold by Fauber Robert on Tuesday, March 6. $7.22 million worth of Moody's Corporation (NYSE:MCO) shares were sold by MCDANIEL RAYMOND W. Huber Linda sold $4.92M worth of stock. 4,344 Moody's Corporation (NYSE:MCO) shares with value of $727,259 were sold by Cantor Richard. Crimmins Michael S also sold $155,763 worth of Moody's Corporation (NYSE:MCO) shares. 5,862 shares valued at $1.02 million were sold by Worrall Blair on Thursday, May 10. $80,480 worth of stock was sold by Duffie Darrell on Monday, April 2.

Investors sentiment increased to 1.35 in 2017 Q4. Its up 0.34, from 1.01 in 2017Q3. It increased, as 28 investors sold Moody's Corporation shares while 162 reduced holdings. 84 funds opened positions while 172 raised stakes. 158.40 million shares or 0.16% more from 158.15 million shares in 2017Q3 were reported. Choate Inv has invested 0.04% in Moody's Corporation (NYSE:MCO). Moreover, Akre Capital Management Ltd Liability Corp has 11.62% invested in Moody's Corporation (NYSE:MCO) for 5.69M shares. Barr E S And reported 0.1% stake. Northern accumulated 1.92M shares. Rice Hall James Limited Liability Corp invested in 0.02% or 3,479 shares. Estabrook holds 0.01% or 600 shares. Perigon Wealth Limited Co reported 20,720 shares. Saturna Corp owns 5,689 shares. Quantum Capital Mngmt Ltd Liability Com Nj has invested 1.14% in Moody's Corporation (NYSE:MCO). Neuberger Berman Ltd Liability has invested 0.26% in Moody's Corporation (NYSE:MCO). Sands Mgmt Llc invested 0.02% in Moody's Corporation (NYSE:MCO). Cornerstone Advsr owns 10,000 shares for 0.17% of their portfolio. Wells Fargo & Com Mn holds 0.02% in Moody's Corporation (NYSE:MCO) or 404,387 shares. Amer Grp reported 81,253 shares. Sarl has invested 0.4% of its portfolio in Moody's Corporation (NYSE:MCO).

The President and CEO of Moodys Corp and firm’s insider Raymond Mcdaniel sold 10,000 shares of the corporation estimated based on $173.2 for each share. The reported shares have a value of precisely $1,731,659 USD. The regulatory filing shows that Raymond Mcdaniel now possess around 0.14% of the New York-based company’s total market cap

Analysts await Moody's Corporation (NYSE:MCO) to report earnings on July, 20. They expect $1.87 earnings per share, up 23.84% or $0.36 from last year’s $1.51 per share. MCO’s profit will be $358.85M for 23.03 P/E if the $1.87 EPS becomes a reality. After $2.02 actual earnings per share reported by Moody's Corporation for the previous quarter, Wall Street now forecasts -7.43% negative EPS growth.

Moody's Corporation provides credit ratings; and credit, capital markets, and economic related research, data, and analytical tools worldwide. The company has market cap of $33.05 billion. It operates through two divisions, Moody's Investors Service and Moody's Analytics. It has a 33.44 P/E ratio. The Moody's Investors Service segment publishes credit ratings on various debt obligations and entities that issue such obligations comprising various corporate and governmental obligations, structured finance securities, and commercial paper programs.

Among 14 analysts covering Moody’s (NYSE:MCO), 3 have Buy rating, 0 Sell and 11 Hold. Therefore 21% are positive. Moody’s has $203.0 highest and $16 lowest target. $158.79’s average target is -7.81% below currents $172.24 stock price. Moody’s had 55 analyst reports since October 5, 2015 according to SRatingsIntel. The stock of Moody's Corporation (NYSE:MCO) earned “Hold” rating by Barclays Capital on Friday, April 28. The firm has “Overweight” rating given on Friday, November 17 by Barclays Capital. The stock of Moody's Corporation (NYSE:MCO) earned “Overweight” rating by Barclays Capital on Tuesday, October 6. The firm has “Neutral” rating given on Wednesday, October 14 by Atlantic Securities. Evercore initiated Moody's Corporation (NYSE:MCO) rating on Thursday, January 7. Evercore has “Hold” rating and $103 target. On Monday, February 12 the stock rating was maintained by Barclays Capital with “Overweight”. As per Monday, November 6, the company rating was maintained by Credit Suisse. The stock of Moody's Corporation (NYSE:MCO) earned “Hold” rating by BMO Capital Markets on Friday, October 13. The rating was downgraded by Barclays Capital on Tuesday, January 10 to “Equal Weight”. The stock of Moody's Corporation (NYSE:MCO) earned “Neutral” rating by UBS on Friday, August 18.

The stock increased 2.86% or $0.58 during the last trading session, reaching $20.88. About 23.90 million shares traded or 109.15% up from the average. Teva Pharmaceutical Industries Limited (NYSE:TEVA) has declined 49.50% since May 17, 2017 and is downtrending. It has underperformed by 61.05% the S&P500.

More notable recent Teva Pharmaceutical Industries Limited (NYSE:TEVA) news were published by: Seekingalpha.com which released: “Teva: It Will Get Worse” on May 14, 2018, also Investorplace.com with their article: “Teva Pharmaceutical Industries Ltd, Once a Falling Machete, Is Spiking — Chase It” published on May 16, 2018, Globes.Co.Il published: “FDA delays approving Perrigo’s generic Teva inhaler” on May 13, 2018. More interesting news about Teva Pharmaceutical Industries Limited (NYSE:TEVA) were released by: Streetinsider.com and their article: “Buffett’s Berkshire 13F Confirms Increase in Apple (AAPL) Stake Along with Increase in Holdings of Teva (TEVA) (More…)” published on May 15, 2018 as well as Seekingalpha.com‘s news article titled: “Teva: A Better Entry Point Post-Results” with publication date: May 06, 2018.

Teva Pharmaceutical Industries Limited develops, makes, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. The company has market cap of $21.26 billion. It operates through two divisions, Generic Medicines and Specialty Medicines. It currently has negative earnings. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.

Moody's Corporation (NYSE:MCO) Institutional Positions Chart

Leave a Reply

Your email address will not be published. Required fields are marked *